摘要
目的观察美托洛尔和氯沙坦合用治疗充血性心力衰竭（CHF）的临床疗效。方法在常规抗心力衰竭治疗的基础上，将196例CHF患者随机分为3组：美托洛尔（Metoprolol，M）组65例、氯沙坦（Losartan，L）组67例、美托洛尔辅氯沙坦（M—L）组64例。美托洛尔根据心功能确定首次剂量，若无不良反应，每周剂量加倍，直到最大耐受量；氯沙坦25—100mg，qd。3组疗程均为6个月。观察治疗前、后各组心功能、左室舒张末期内径（LVD）、左室收缩末期内径（LVS）、左室射血分数（EF）、心输出量（CO）、心胸比例（C／T）和血浆去甲肾上腺素（NE）的变化。结果M-L组疗效明显优于单纯M和L组。结论美托洛尔和氯沙坦合用治疗CHF安全有效，可有效改善心功能、提高生活质量，值得临床推广。
Objecive To investigate the efficacy of metoprolol combined with losartan potassium on patients with congestive heart failure （CHF）. Method On the basis of conventional treatment, 196 cases of CHF patients were randomly divided into three groups：65 cases in metoprolol（M） group,67 cases in losartan potassium（ losartan, L） group and 64 cases in metoprolol auxiliaried losartan（M-L） group. The first dose of metoprolol was determined according to heart function, if there were no adverse reactions, their weekly dose was doubled until the maximum tolerance. Losartan potassium was given,25 - 100mg, qd. The treatment course of three groups were all six months. Before and after treatment, the changes of cardiac function,left ventricular end-diastolic dimension （ LVD ） , left ventricular end-systolic dimension （ LVS ） , left ventrieular ejection fraction （ EF）, cardiac output（CO）, cardiothoracic ratio （C/T） and norepinephrine （NE） in each group were observed. Results The therapeutic effect of M-L group was better than those of M group and L group. Conclusions For CHF patients, the combination therapy of metoprolol and losartan potassium is safe and effective. It can effectively improve the cardiac function and quality of life, it is worth promoting in clinic.
出处
《现代诊断与治疗》
CAS
2009年第6期324-326,共3页
Modern Diagnosis and Treatment
关键词
充血性心力衰竭
美托洛尔
氯沙坦
心功能
Congestive heart failure
Metoprolol
Losartan
Cardiac function
